Related Experiment Videos
Alterations in IRF1/IRF2 expression in acute myelogenous leukemia
H D Preisler1, S Perambakam, B Li
1Rush Cancer Institute, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612, USA. hpreisler@rush.edu
American Journal of Hematology
|September 18, 2001
Summary
The ratio of interferon response gene 1 (IRF1) to interferon response gene 2 (IRF2) expression is lower in acute myeloid leukemia (AML) patients. This ratio may be normalized in some AML patients with IL4 treatment.
Area of Science:
- Molecular Biology
- Oncology
- Immunology
Background:
- Interferon response genes 1 (IRF1) and 2 (IRF2) regulate myeloid cell differentiation and proliferation.
- IRF1 acts as an anti-oncogene, while IRF2 functions as an oncogene.
- The balance of IRF1 and IRF2 expression is crucial in cellular regulation.
Purpose of the Study:
- To compare IRF1 and IRF2 expression levels and their ratios in acute myeloid leukemia (AML) and normal bone marrow.
- To investigate the association between IRF1:IRF2 ratios and specific mutations (ras, fms, p53) in AML.
- To explore the potential of IL4 in normalizing the IRF1:IRF2 ratio in AML.
Main Methods:
- Quantitative analysis of IRF1 and IRF2 gene expression in AML and normal bone marrow samples.
- Comparison of gene expression ratios between patient groups.
- Correlation analysis of IRF1:IRF2 ratios with ras, fms, and p53 mutation status.
Main Results:
- The IRF1:IRF2 expression ratio was significantly lower in AML marrow cells compared to normal marrow cells (median ratio 1.33 vs. 2.97, P = 0.003).
- p53 mutations were associated with higher IRF1:IRF2 ratios than wild-type p53 (median 1.701 vs. 1.135, P = 0.014).
- Ras or fms mutations did not affect the IRF1:IRF2 expression ratio.
Conclusions:
- A decreased IRF1:IRF2 ratio may be linked to leukemic transformation in AML.
- The IRF1:IRF2 ratio is modulated by p53 status in AML.
- Interleukin-4 (IL4) administration shows potential for normalizing the IRF1:IRF2 ratio in some AML patients.